Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06336291 · ClinicalTrials.gov registry record · Phase 2
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
A Phase 2 study of Glioblastoma, sponsored by Philogen S.p.A..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 8
- Study locations
NCT06336291: Recruiting Phase 2 study of Glioblastoma, sponsored by Philogen S.p.A..
NCT06336291 is a Phase 2 study of Glioblastoma that is actively recruiting participants, run by Philogen S.p.A.. The registered enrollment target is 90 participants, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (17% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06336291, a Phase 2 study of Glioblastoma, is actively recruiting participants, sponsored by Philogen S.p.A..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 8
- Study locations
Study Summary
The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence
Primary Outcome
Occurence of AEs according to CTCAE v.5.0
Conditions Studied
Interventions
- DRUG Lomustine
- DRUG L19TNF
Study Locations (8)
Massachusetts
- Massachusetts General Hospital (MGH) - Boston
- Beth Israel Deaconess Medical Center (BIDMC) - Boston
- Dana-Farber Cancer Institute (DFCI) - Boston
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
Illinois
- Northwestern Memorial Hospital - Chicago
New York
- Memorial Sloan Kettering Cancer Center - New York
Virginia
- University of Virginia (UVA) - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-05-22 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT06336291 shows while recruiting
NCT06336291 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Lomustine is the first listed.
NCT06336291 lists 8 locations in 5 states (Massachusetts, Pennsylvania, Illinois).
Frequently Asked Questions
What is clinical trial NCT06336291 about?
NCT06336291 is a clinical study titled "A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence". The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence
What is the current status of trial NCT06336291?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-05-22. Estimated completion is 2026-06.
What conditions does trial NCT06336291 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT06336291?
The interventions under investigation include: Lomustine (DRUG), L19TNF (DRUG).
Who is sponsoring clinical trial NCT06336291?
This trial is sponsored by Philogen S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06336291 being conducted?
This trial has 8 study locations across Illinois, Massachusetts, New York, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06336291's enrollment target sits among peer trials
90 51st of 199 higher than 148 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI